Johnson & Johnson Shares Dip Despite Raised Outlook; AstraZeneca Acquires Lung Cancer Drug Rights
Despite raising its full-year revenue forecast, Johnson & Johnson's shares fell nearly 3% due to underperformance in oncology and medical device divisions. Meanwhile, AstraZeneca agreed to a $600 million upfront deal with Dizal for global rights to lung cancer drug Zegfrovy.